T1D Exchange and DreaMed Diabetes recently announced that it has entered a partnership to provide six clinics in its Quality Improvement Collaborative with DreaMed Advisor Pro to improve insulin treatment plans.
The Quality Improvement Collaborative (QIC) is a data platform of 30,000 people with learning collaborative in 11 diabetes centers in the U.S. that are treating people who have Type 1 diabetes. DreaMed Advisor Pro is an artificial intelligence-based decision support system that will help T1D Exchange’s systems determine high-risk patients and the best treatment plans for maintaining balanced glucose levels.
“This partnership represents a whole new path toward impacting health outcomes for people with T1D,” interim chief operating officer at T1D Exchange said in a press release. “DreaMed’s Advisor Pro software will enable the clinics in our Quality Improvement Collaborative to understand how AI can support diabetes treatment decisions and better manage insulin therapy. We are excited to have DreaMed as our partner.”
DreaMed Advisor Pro is a cloud-based platform that analyzes data from continuous glucose monitors, self-monitoring blood glucose meters and insulin pump data to determine the best insulin delivery recommendations. It uses an event-based learning process to use different factors like basal rate, carbohydrate ratio and a correction factor to recommend the best treatment option. The insulin dosage recommendations are sent directly to a monitoring clinician who can adjust the patient’s diabetes management devices.
“In today’s rapidly changing world, technology offers a critical path to accelerate meaningful change in the management of T1D,” said Eran Atlas, co-founder and CEO of DreaMed. “From the standardization of care to optimizing outcomes, we are honored by this opportunity. It’s a true partnership among the scientists, clinicians, patients and caregivers.”
“Artificial intelligence-based decision support can save persons with diabetes, physicians and other members of the diabetes care team time. This means that the person with diabetes has to spend less time thinking about how to optimize their diabetes management and that clinicians can spend more time talking face to face with individuals with diabetes, rather than sifting through data reports to extract insights,” said endocrinologist Mark Clements, a faculty member at the Children’s Mercy Kansas City Diabetes Center and a member of the T1D Exchange QIC.
